Evaluation of the Clinical Features of Infertile Women With Subclinical Hypothyroidism in Relatively High-Iodine-Intake Area

Seigo Tachibana, Kyoko Shirotu, Tetsuhiro Futata, Yumi Nagata, Hiroyuki Yamashita, Toshihiko Yanase

Abstract

Background: It is well known that hypothyroidism may cause menstrual abnormalities, infertility, increased risk of miscarriage, obstetric complications, and adverse outcomes in offspring. On the other hand, some studies have reported the efficacy of supplementation of levothyroxine (LT4) for subclinical hypothyroidism (SCH) in infertile women. The aim of this study was to evaluate the clinical features of infertile SCH patients in Japan.

Methods: A total of 156 SCH patients were enrolled in this study. They were divided into two groups: 76 patients who showed positivity for anti-thyroglobulin antibody (TgAb) and/or thyroid peroxidase antibody (TPOAb) were categorized into group A, while 80 patients who showed negativity for both TgAb and TPOAb were categorized into group B. Between these two groups, we evaluated the following factors: age, thyroid function before treatment, presence of hyperprolactinemia, necessary dose of LT4 for correction of thyroid function, thyroid function after treatment, history of abortion, history of pregnancy after treatment, and dose of LT4 before delivery in pregnant subjects.

Results: All of the above investigated factors showed no significant differences between groups A and B. However, a notable point was that the necessary dose of LT4 for correcting thyroid function did not show a significant difference, regardless of anti-thyroid autoantibody.

Conclusion: In Japan, an area of high iodine intake, in infertile women with SCH, the administration of an adequate dose of LT4 is recommended, regardless of the presence of chronic thyroiditis.

Keywords: Subclinical hypothyroidism; Infertility; Chronic thyroiditis

Introduction

It is well known that hypothyroidism may affect the hypothalamic-pituitary-gonadal axis and the peripheral metabolism of sex steroids [1-4]. Hypothyroidism may cause menstrual abnormalities, infertility, increased risk of miscarriage, obstetric complications, and adverse outcomes in offspring [3-5]. Most cases of hypothyroidism are associated with autoimmune thyroiditis, and the prevalence of thyroid autoimmunity among infertile patients was found to be higher than that of a similar age group [6]. In addition, it is known that women with chronic thyroiditis might be at an increased risk of miscarriage and obstetric complications, even in a subclinical hypothyroidism and euthyroid state [3, 7].

Some studies have reported the efficacy of supplementation of levothyroxine (LT4) for subclinical hypothyroidism (SCH) in infertile women. In these studies, adequate supplementation of LT4 improved embryo quality and pregnancy outcome [4, 8]. In Japan, a country with excessive iodine intake, treatment for SCH in infertile women has generally been performed. However, there may be differences in the clinical features of infertile SCH patients between high iodine intake areas and elsewhere. In this study, we evaluated the clinical features of infertile SCH patients in Japan.

Materials and Methods

Subjects

Between January 2009 and December 2012, 417 patients suffering from infertility were introduced to Futata Tetsuhiro Clinic because of a suspicion of thyroid dysfunction detected at screening for the differential diagnosis of infertility. Of these, 156 patients were diagnosed with SCH because the concentra-
The clinical and biochemical profile of the subjects is shown in Table 1.

### Treatment

LT4 was prescribed to these SCH patients. When TSH was corrected to the normal range, the dose of LT4 was continued. In addition, when patients were pregnant, the dose of LT4 was adjusted by TSH concentration as follows. In the first trimester, the target of TSH was below 2.5 μIU/mL, and in the second and third trimesters, the target of TSH was below 3.0 μIU/mL.

### Laboratory measurements

TSH, FT4, anti-thyroglobulin antibody (TgAb) and thyroid peroxidase antibody (TPOAb) were examined using ECLusys kit (Roche Diagnostics, Penzberg, Germany). The reference ranges were as follows: TSH 0.5 - 5.0 mIU/L, FT4 0.9 - 1.7 ng/dL, TgAb < 28 IU/mL, and TPOAb < 16 IU/mL.

### Study protocol

This was a retrospective chart review. The total of 156 patients were divided into the following two groups: 76 patients who showed positivity for TgAb and/or TPOAb were categorized into group A, while 80 patients who showed negativity for both TgAb and TPOAb were categorized into group B. Between these two groups, we evaluated the following factors: age, thyroid function (TSH, FT4) before treatment, presence of hyperprolactinemia (prolactin > 20 ng/mL), necessary dose of LT4 for correction of thyroid function, thyroid function (TSH, FT4) after treatment, history of pregnancy after treatment, history of abortion, and dose of LT4 before delivery in pregnant subjects. In addition, these subjects were also divided into the following two groups: 27 patients whose TSH was above 10 μIU/mL were categorized into group C, while 129 patients whose TSH was below 10 μIU/mL were categorized into group D. Between these two groups, we evaluated the following factors: presence of hyperprolactinemia, history of abortion, history of pregnancy after treatment, and dose of LT4 before delivery in pregnant subjects.

### Statistical analysis

In these two groups, statistical analysis was performed using Fisher’s exact test and Mann-Whitney’s U test. These analyses were performed with JMP ver. 6.0 (SAS Institute Inc.).

### Results

As shown in Table 2, between groups A and B, age, thyroid function (TSH, FT4) before treatment, presence of hyperprolactinemia, and necessary dose of LT4 for correction of thyroid function did not show a significant difference. Thyroid function (TSH, FT4) after treatment, history of abortion, history of pregnancy after treatment, and dose of LT4 before delivery in pregnant subjects also did not show any significant differences. In this retrospective review, all investigated factors showed no significant statistical differences between groups A and B.

As shown in Table 3, between groups C and D, the existence of hyperprolactinemia, history of abortion, and history of pregnancy after treatment also did not show significant differences. Only the dose of LT4 before delivery in pregnant subjects showed a significant difference (P = 0.01).

### Table 1. The Clinical and Biochemical Profile of Subjects

| Age       | 35.26 ± 4.05 years |
| TSH       | 7.67 ± 3.38 μIU/mL |
| free T4   | 1.08 ± 0.18 pg/dL  |
| Anti-thyroid antibody (positive/negative) | 76:80 |

Data are mean ± SD.

### Table 2. Results of Statistical Analysis Between Groups A and B (n = 156)

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>B</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>35.2 ± 3.8</td>
<td>35.3 ± 4.3</td>
<td>1.00</td>
</tr>
<tr>
<td>TSH before treatment</td>
<td>7.91 ± 4.00</td>
<td>7.44 ± 2.66</td>
<td>0.59</td>
</tr>
<tr>
<td>FT4 before treatment</td>
<td>1.07 ± 0.20</td>
<td>1.09 ± 0.17</td>
<td>0.50</td>
</tr>
<tr>
<td>Hyperprolactinemia (+):(-)</td>
<td>5:71</td>
<td>6:74</td>
<td>1.00</td>
</tr>
<tr>
<td>Necessary dose of LT4 for correction of thyroid function</td>
<td>37.83 ± 21.21</td>
<td>37.50 ± 21.33</td>
<td>0.85</td>
</tr>
<tr>
<td>TSH after treatment</td>
<td>2.20 ± 0.93</td>
<td>2.37 ± 0.92</td>
<td>0.20</td>
</tr>
<tr>
<td>FT4 after treatment</td>
<td>1.29 ± 0.16</td>
<td>1.31 ± 0.16</td>
<td>0.55</td>
</tr>
<tr>
<td>History of abortion (+):(-)</td>
<td>24:52</td>
<td>21:59</td>
<td>0.48</td>
</tr>
<tr>
<td>Pregnancy after treatment (+):(-)</td>
<td>48:28</td>
<td>51:29</td>
<td>1.00</td>
</tr>
<tr>
<td>Dose of LT4 before delivery in pregnant subjects</td>
<td>52.34 ± 27.94</td>
<td>47.44 ± 29.13</td>
<td>0.44</td>
</tr>
</tbody>
</table>

Data are mean ± SD.
Discussion

In this retrospective study, no significant differences between groups A and B were observed. A notable point was that the necessary dose of LT4 for correcting thyroid function did not show a significant difference, regardless of anti-thyroid autoantibody. A consensus about LT4 treatment for infertile women with SCH and anti-thyroid autoantibody has already been reached; on the other hand, it is controversial whether LT4 treatment for infertile women with SCH without anti-thyroid autoantibody should be recommended [9-11]. However, Maruo et al reported that thyroid hormones synergize with FSH to exert direct stimulatory effects on granulosa cell functions, including morphological differentiation, luteinizing hormone/human chorionic gonadotropin (hCG) receptor formation, and steroidogenic enzyme induction, and decreases in ovarian functions during hypothyroidism may account for diminished responsiveness of the granulosa cells to FSH [1]. In addition, Abdel Rahman et al reported that LT4 treatment for infertile subjects should be recommended to achieve clinical pregnancies in women with SCH who are undergoing in vitro fertilization-intracytoplasmic sperm injection [8]. LT4 is one of the safest drugs in that it seldom shows adverse effects, and is particularly cost-effective. Therefore, even if anti-thyroid autoantibodies are negative, appropriate supplementation of LT4 for infertile women with SCH should be considered because the necessary dose of LT4 for correcting thyroid function did not show a significant difference between the anti-thyroid autoantibody-positive and -negative groups.

On the other hand, in several studies, patients with positive TgAb and/or TPOAb tended to show a high miscarriage rate [12-14]. However, in our study, we could not observe such a tendency. Considering this point, this study was retrospective, and most of our subjects have multiple causes of infertility. In addition, in this series, factors associated with habitual abortion, such as antinuclear antibody and anticardiolipin antibody, were not fully evaluated. These points might have influenced this discrepancy between several reports and our results. Therefore, our retrospective study could not show adequate data associated with anti-thyroid antibody and miscarriage. However, Yoshioka et al reported that, in infertile subjects corrected to a euthyroid state by LT4 administration, the necessary dose of LT4 is recommended, regardless of the presence of chronic thyroiditis. In addition, the necessary dose of LT4 did not show remarkable changes associated with the causes of SCH.

Conflicts of Interest

None of the authors has any potential conflicts of interest associated with this research.

References

2. Longcope C, Abend S, Braverman LE, Emerson CH. Androstenedione and estrone dynamics in hypothyroid...


